As previously disclosed by Peak Bio, Inc., a Delaware corporation (the "Company") on its Current Reports on Form 8-Kfiled with the Securities and Exchange Commission (the "SEC") on November 2, 2022 and January 4, 2023, pursuant to subscription agreements dated October 31, 2022 and December 30, 2022, respectively, the Company previously issued to certain accredited investors (the "PIPE Investors"), warrants to purchase shares of the Company's common stock, par value $0.0001 per share (the "Common Stock") with an exercise price of $0.01 per share (the "PIPE Warrants").
Between October 31, 2023 and November 1, 2023, the PIPE Investors exercised the PIPE Warrants to purchase a total of 492,045 shares of the Company's Common Stock at $0.01 per share for a total purchase price of $4,920.45. The Common Stock issued to the PIPE Investors will not be registered under the Securities Act of 1933, as amended (the "Securities Act") in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder.
Peak Bio Inc. published this content on 02 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 November 2023 20:11:14 UTC.
Peak Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on commercializing therapeutics that aim to improve and address unmet medical needs for patients with inflammatory, rare and specialty diseases and cancer. The Companyâs lead product candidate, PHP-303, is a small molecule, fifth generation, phase II clinical-ready neutrophil elastase (NE) inhibitor (NEI). PHP-303 is an oral, once daily, 0.65 nanomolar, selective, small molecule reversible inhibitor of NE designed to inhibit its bioactive form that the Company is developing for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic disorder that may result in lung disease or liver disease and, potentially, acute respiratory distress syndrome (ARDS). The Companyâs advanced platform in oncology utilizes its toxin, PH-1 or Thailanstatin, to generate a pipeline of antibody-drug-conjugates (ADC) product candidates that are differentiated from traditional ADC-based therapies.
PEAK BIO, INC. 
